InvestorsHub Logo
Followers 1
Posts 234
Boards Moderated 0
Alias Born 10/03/2014

Re: Polyphemus post# 10

Wednesday, 06/05/2019 7:49:05 PM

Wednesday, June 05, 2019 7:49:05 PM

Post# of 1032
I don’t think we differ greatly. I agree with turning the operation around as that will placate the shareholders.

I could also see out licensing the RA.

I agree that they have to find a way to work as a nano company to accomplish results without utilizing money. They have already invested as a big pharma would. The infrastructure is built. The results of clinical trials are there. The work to satisfy the HEOR guys is there. The KOL influence is there. They are part of the physician patient pharmacy relationship.

MSL’s as the primary source of promotion is big company. Expensive as a stand alone. Large areas of geography and docs are left uncovered. They need a nano strategy to get patients and to broaden reach.

BTW, I am a nano guy.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ECOR News